The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes

Bon Ham Yip, Violetta Steeples, Emmanouela Repapi, Richard N. Armstrong, Miriam Llorian, Swagata Roy, Jacqueline Shaw, Hamid Dolatshad, Stephen Taylor, Amit Verma, Matthias Bartenstein, Paresh Vyas, Nicholas C. P. Cross, Luca Malcovati, Mario Cazzola, Eva HellströmLindberg, Seishi Ogawa, Christopher W. J. Smith, Andrea Pellagatti, Jacqueline Boultwood

## Supplementary Information

## Supplemental Methods

## Real-time quantitative PCR

The expression level of U2AF1 was determined by real-time quantitative PCR. The $\beta 2$ microglobulin gene was used to normalize for differences in input cDNA. Pre-developed TaqMan Assays were used (Assays-on-Demand, Applied Biosystems, Foster City, CA, USA) and reactions were run on a LightCycler 96 Real-Time PCR System (Roche). Each sample was run in triplicate and the expression ratios were calculated using the $\Delta \Delta \mathrm{C}_{\mathrm{T}}$ method.

## Western blot

Western blot was performed using the Invitrogen NuPage Novex 4-12\% Bis-Tris Gels as previously described (1). Anti-FLAG M2-Peroxidase (HRP) antibody (Sigma Aldrich), anti-U2AF35 antibody (Abcam ab86305), anti-ITGB3BP antibody (HPA028463; Atlas antibodies), and anti-beta actin antibody (HRP) (Abcam ab197277) at 1:2500, 1:2000, 1:500 and 1:30000 dilution respectively were used.

## Cell Growth Assay

Transduced cells on day 8 were seeded into 96 -well plates ( 20,000 cells $/ 0.2 \mathrm{~mL}$ ) and viable cell counts were determined by trypan blue exclusion for 6 consecutive days. Medium was replenished every second day to maintain the same volume.

## May-Grünwald-Giemsa staining

Cytospin slides of cultured granulomonocytic cells were prepared and stained with May-Grünwald and Giemsa solution according to the manufacturer's instructions (Sigma Aldrich).

## Pyrosequencing

PCR and Sequencing primers were designed using PyroMark Assay Design 2.0 software and are shown in Supplemental Table 1. PCR of colony cDNA was performed with the PyroMark PCR kit (Qiagen) using the standard component mix ( 1.5 mM MgCl$)_{2}$ ) and thermocycling conditions $\left(55^{\circ} \mathrm{C}\right.$ annealing temperature). Pyrosequencing was performed on a PyroMark Q24 instrument (Qiagen) according to the manufacturer's recommendations.

## SYBR green real-time qPCR

Primers described in Park et al. (2) were used to perform a SYBR green real-time qPCR to assess ATG7 polyadenylation site usage. Samples were run on a Roche Lightcycler 96 using Roche lightcycler 480 SYBR green I master according to the manufacturer's protocol.

## Cloning and Sanger sequencing

The coding sequence of the H2AFY and STRAP genes were amplified from cDNA obtained from erythroid and granulomonocytic colonies by PCR using Phusion high fidelity DNA polymerase (NEB). PCR products were purified using a QIA quick gel extraction kit (Qiagen) and A tailed using Maxima hot start PCR mastermix. PCR products were inserted into the pCR4-TOPO vector using a TOPO TA Cloning Kit (Life technologies) and transformed in DH5 $\alpha$ chemically competent cells (Life technologies). These were grown at $37^{\circ} \mathrm{C}$ on LB Agar plates supplemented with $100 \mu \mathrm{~g} / \mathrm{ml}$ ampicillin (Sigma). Individual colonies were picked and expanded in LB medium with $100 \mu \mathrm{~g} / \mathrm{ml}$ ampicillin, and plasmid DNA was then extracted using a Qiaprep spin miniprep kit (Qiagen). Plasmid insert sequences were obtained by Sanger sequencing (Source Bioscience) using M13F and M13R primers.

## References

1. Yip BH, et al. Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. Leukemia. 2012;26(9):2154-2158.
2. Park SM, et al. U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 PremRNA 3' End Formation. Mol Cell. 2016;62(4):479-490.

Supplemental Figure 1

A



B

Erythroid


Granulomonocytic


C
EV
Serine


U2AF1WT
Serine


U2AF1S34F Phenylalanine


D
Erythroid
Granulomonocytic


E


F


G


Supplemental Figure 1. Expression of U2AF1WT and U2AF1S34F in hematopoietic CD34+ progenitors. (A) Schematic diagram showing the retroviral pGCDNsam-IRES-neomycin plasmids containing U2AF1WT or U2AF1S34F cDNA (left). Schematic diagram showing the culture conditions used to obtain erythroid and granulomonocytic cells following retroviral transduction of a plasmid expressing U2AF1WT or U2AF1S34F cDNA into hematopoietic progenitors (right). (B) Taqman qRT-PCR to determine the relative expression levels of $U 2 A F 1 W T$ or $U 2 A F 1 S 34 F$ transcripts in transduced cells differentiating towards erythroid and granulomonocytic cells harvested on Day 11. Results in each bar graph were obtained from 6 independent experiments. (C) Sanger sequencing of cDNA from transduced cells confirming the expression of the U2AF1S34F mutation. (D) Expression of U2AF1 ${ }^{W T}$ and U2AF1 ${ }^{\text {S34F }}$ at different time points in transduced erythroid and granulomonocytic cells in culture. Quantification of protein expression levels was performed by ImageJ. (E) Cell cycle analysis of transduced erythroid cells expressing U2AF1WT or U2AF1 ${ }^{\mathrm{S} 34 \mathrm{~F}}$ on day 11 of culture. Results were obtained from 6 independent experiments. (F) Granulomonocytic differentiation in transduced granulomonocytic cells expressing U2AF1WT or U2AF1s34F. Median fluorescence intensity (MFI) of forward scatter (as a measure of cell size) of transduced granulomonocytic cells expressing U2AF1WT or U2AF1S34F on day 20 of culture. Results were obtained from 5 independent experiments. (G) Apoptosis in transduced granulomonocytic cells expressing U2AF1 ${ }^{\text {WT }}$ or U2AF1S34F. Apoptosis was measured by Annexin V staining and flow cytometry in transduced granulomonocytic cells expressing U2AF1WT or U2AF1 ${ }^{\mathrm{S} 34 \mathrm{~F}}$ on day 11 of culture. Results were obtained from 7 independent experiments. Bar graphs show mean+SEM. ${ }^{*} P<0.05,{ }^{* *} \mathrm{P}<0.01$ and ${ }^{* * *} \mathrm{P}<0.001$, 1-way ANOVA with repeated measures using Tukey's post-test.


Supplemental Figure 2. Splice site strengths and BP scores for cassette exons regulated by U2AF1S34F. (A) Schematic representation of cassette exons (orange) and locations of the different features analyzed. (B) Splice site strength and (C) BP scores were determined for the different data sets: Exons more Included, more Skipped upon U2AF1 ${ }^{\text {S34F }}$ overexpression and non regulated SE control exons. For each data set, splice site scores (B) or BP scores (C) are plotted; 5'ss (blue), 3'ss (orange), upstream 5'ss (white) and downstream 3'ss (white). Boxplot's whiskers represent 1.5 IQR and outliers are not shown. Statistically significant differences (Kruskal-Wallis followed by Mann-Whitney U tests with Bonferroni correction) are marked, p-value $<0.05\left(^{*}\right)$, p-value $<0.01\left(^{* *}\right)$, p-value $<0.001\left(^{* * *}\right.$ ), and lines are colored to show comparisons between 3'ss (orange) or 5'ss (blue).

Genes aberrantly Genes expressed in spliced in erythroid colonies only
granulomonocytic colonies

Genes aberrantly spliced in granulomonocytic colonies only


B


Supplemental Figure 3. Expression levels of aberrantly spliced genes. (A) Venn diagrams showing the overlap between genes showing aberrant splicing in erythroid colonies and genes that are expressed in granulomonocytic colonies, and between genes showing aberrant splicing in granulomonocytic colonies and genes that are expressed in erythroid colonies. The large majority of genes aberrantly spliced in either erythroid or granulomonocytic lineage only were also expressed in the other lineage. (B) Violin plots showing the distribution of the expression levels (log2rpkm) of the aberrantly spliced genes identified in our study (from Figure 3F).

Supplemental Figure 4

B
ITGB3BP
A

| Gene | Aberrant splicing event | Affected lineage |
| :--- | :--- | :--- |
| SMARCA5 | Skipping of exon 14 | erythroid |
| ITGB3BP | Inclusion of exon 2 | granulomonocytic |
| ATR | Inclusion of exon 47 | granulomonocytic |

C SMARCA5




| D |
| :---: |
|  |
|  |
|  |
| 46 |



Supplemental Figure 4. Measurement of lineage-specific splicing alterations in U2AF1S34F erythroid and granulomonocytic cells by isoform-specific qRT-PCR. (A) Genes of interest that exhibit differential aberrant splicing between U2AF1534F erythroid and granulomonocytic colonies (ITGB3BP, SMARCA5 and ATR). Measurement of lineagespecific splicing alteration in (B) ITGB3BP, (C) SMARCA5 and (D) ATR. Left panel: sashimi plots illustrating RNA sequencing results of $I T G B 3 B P, S M A R C A 5$ and $A T R$ in erythroid and granulomonocytic colonies. For each gene, only the region affected by aberrant splicing is shown and highlighted in grey. Right panels: expression of the isoform associated with aberrant splicing by U2AF1S34F in transduced cells was measured by isoform-specific qRT-PCR relative to EV and U2AF1WT control (red bars: erythroid cells; blue bars: granulomonocytic cells). Results in each bar graph were obtained from 5 independent experiments. Bar graphs show mean+SEM. *P<0.05, 1-way ANOVA with repeated measures using Tukey's post-test.

H2AFY 1.2



















 minn in













| Score | Expect | Identities | Gaps | Strand |
| :--- | :--- | :--- | :--- | :--- |
| 1380 bits(747) | 0.0 | $747 / 747(100 \%)$ | $0 / 747(0 \%)$ | Plus/Plus |

Query 1 TGTCAAGACTGTGGATTTCACGCAGGATAGTAATTATTTGTTAACCGGGGGACAGGATAA 60 Sbjct 306 TGTCAAGACTGTGGATTTCACGCAGGATAGTAATTATTTGTTAACCGGGGACAGGATAA Query 61 ACTGTTACGCATATATGACTTGAACAAACCTGAGGCAGAACCTAAGGAAATTAGGGGTCA 120 Sbjct 366 ACTGTTACGCATATATGACTTGAACAAACCTGAAGCAGAACCTAAGGAAATTAGTGGTCA 425 Query 121 TACTTCTGGTATaaaaaaaGCTCTGTGGGGCAGTGAGGATAAACAGATTCTTTCTGGTGA 180 Sbjct 426 TACTTCTGGTATAAAAAAAGCTCTGTGGTGCAGTGAGGATAAACAGATTCTTTCTGCTGA 485 Query 181 TGACAAAACTGTTCGACTTTGGGATCATGCTACTATGACAGAAGTGAAATCTCTAAATTT 240 Query 241 TAATATGTCTGTTAGTAGTATGGAATATATTCCTGAGGGAGAGATTTTGGTTATAACTTA 300 sbjct 546 TAATATGTCTGTTAGTAGTATGGAATATATTCCTGAGGGAGAGATTTTGGTTATAACTTA 605 Query 301 TGGACGATCTATTGCTITTCATAGTGCAGTAAGTTTGGACCCAATTAAATCCTITGAAGC 360 Query 361 TCCTGCAACCATCAATTCTGCATCTCTTCATCCTGAGAAAGAATTTCTTGTTGCAGGCGG 420 Sbjct 666 TCCTGCAACCATCAATTCTGCATCTCTTCATCCTGAGAAAGAATTTCTTGTTGCAGGCGG 725 Query 421 TGAAGATTYTAAACTTTATAAGTATGATTATAATAGTGGAGAAGAATTAGAATCCTACAA 480 sbjct 726 TGAAGATTYTAAACTTTATAAGTATGATTATAATAGGGGAGAAGAATTAGAATCCTACAA 785 Query 481 GGGACACTTTGGTCCTATTCACTGTGTGAGATTTAGTCCTGATGGAGACTCTATGCCAG 540 Sbjct 786 GGGACACTTTGGTCCTATTCACTGTGTGAGATTTAGTCCTGATGGAGAACTCTATGCCAG 845 Query 541 TGGTTCAGAAGATGGAACATTGAGACTATGGCAAACTGTGGTAGGAAAAACGTATGGCCT 600 sbjct 846 TGGTTCAGAAGATGGAACATTGAGACTATGGCAAACTGTGGTAGGAAAAACGTATGGCCT 98 Query 601 ITGGAAATGTGTGCTTCCTGAAGAAGATAGTGGTGAGCTGGCAAAGCCAAAGATTGGTT 660 sbjct 906 TTGGAAATGTGTGCTTCCTGAAGAAGATAGTGGTGAGCTGGCAAAGCCAAAGATTGGTTT 965
 Query 721 TCCTTCAGCTCCTGATGTTAAGGCCTG 747 sbjct 1026 TCCTTCAGCTCCTGATGTTAAGGCCTG 1052

| Score | Expect | Identities | Gaps | Strand |
| :--- | :--- | :--- | :--- | :--- |
| 1365 bits(739) | 0.0 | $739 / 739(100 \%)$ | $0 / 739(0 \%)$ | Plus/Plus |

Query 1 TGAGACAGACGCCGCTCACCTGCTCTGGCCACACGCGACCCGTGGTTGATTTGGCCTTCA 60 Sbjet 8 TGAGACAGACGCCGCTCACCTGCTCTGGCCACACGCGACCGTGGTGATTTGGCCTICA 67
Query 61 GTGGCATCACGCCTTATGGGTATTTCTTAATCAGCGGTTGCAAAGATGGTAAACCTATGC 120
Sbjct 68 GTGGCATCACGCCTTATGGGTATTTCTTAATCAGCGCTTGCAAAGATGGTAAACCTATGC 127
Query 121 TACGCCAGGGAGATACAGGAGACTGGATTGGAACATITTTGGGTCATAAAGGTGCTGTTT 180

Query 181 GGGGTGCAACACTGAATAAGGATGCCACCAAAGCAGCTACAGCAGCTGCAGATTTCACAG 240
Sbjct 188 GGGGGCAACACTGAATAAGGATGCCACCAAAGCAGCTACAGCAGCTGCAGATTICACAG 247
Query 241 CCAAAGTGTGGGATGCTGTCTCAGGAGATGAATTGATGACCCTGGCTCATAAACACATTG 300
Sbjct 248 CCAAAGTGTGGGATGCTGTCTCAGGAGATGAATTGATGACCCTGGCTCATAAACACATTG 307
Query 301 TCAAGACTGTGGATTTCACGCAGGATAGTAATTATTTGTTAACCGGGGGACAGGATAAAC 360
sbjct 308 TCAAGACTGTGGATTTCACGCAGGATAGTAATTATTTGTTAACCGGGGGACAGGATAAAC 367
Query 361 TGTTACGCATATATGACTTGAACAAACCTGAAGCAGAACCTAAGGAAATTAGTGGTCATA 420
sbjct 368 IGTTACGCATATAGGACTTGACAACCTGAAGCAGAACCTAGGGAATAGGGGTCATA 427
Query 421 CTTCTGGTATaaaaaaaGCTCTGTGGTGCAGGGAGGTAAACAGATTCTTTCTGCTGATG 480
Sbjct 428 CTTCTGGTATAAAAAAAGCTCTGTGGTGCAGTGAGGATAAACAGATTCTTTCTGCTGATG 487
Query 481 ACAAAACTGTTCGACTTTGGGATCATGCTACTATGACAGAAGTGAAATCTCTAAATITTA 540
Sbjct 488 ACAAAACTGTTCGACTTTGGGATCATGCTACTATGACAGAAGTGAAATCTCTAAATTTTA 547
Query 541 ATATGTCTGTTAGTAGTATGGAATATATTCCTGAGGGAGAGATTTTGGTTATAACTTATG 600
Sbjct 548 ATATGTCTGTTAGTAGTATGGAATATATTCCTGAGGGAGAGATTTTGGTTATAACTTATG 607
Query 601 GACGATCTATTGCTTTTCATAGTGCAGTAAGTTTGGACCCAATTAAATCCTTTGAAGCTC 660
sbjct 608 GACGATCTATIGCTYTCATAGGGCAGAAGTTTGGACCCAATAAAACCTHGAGGCTC 667
Query 661 CTGCAACCATCAATTCTGCATCTCTTCATCCTGAGAAAGATTTCTTGTGGCAGGCGGTG 720
sbjct 668 CTGCAACCATCAATTCTGCATCTCTCATCCTGAGAAAGAATTTCTTGTTGCAGGCGGTG 727
Query 721 AAGATYTTAAACTTTATAA 73
Sbjct 728 AAGATTTTAAACTTTATAA 746



Query 1 GACAGGATAAACTGTTACGCATATATGACTTGAACAAACCTGAAGCAGAACCTAAGGAAA 60 sbjct 220 GACAGGATAACTGTTACGCATATATGACTGAACAAACCTGAGCAGAACCTAAGAAA 279 Query 61 TTAGTGGTCATACTTCTGGTATaaaaaaaGCTCTGTGGTGCAGTGAGGATAAACAGATTC 120 sbjct 280 TTAGTGGTCATACTTCTGGTATAAAAAAAGCTCTGTGGTGCAGTGAGGATAAACAGATTC 339
Query 121 ITTCTGCTGATGACAAAACTGTTCGACTTTGGGATCATGCTACTAAGACAGAAGTGAAAT 180
sbjct 340 TTTCTGCTGATGACAAAACTGTTCGACTTTGGGATCATGCTACTATGACAGAAGTGAAAT 399
Query 181 CTCTAAATTTTAATATGTCTGITAGTAGTATGGAATATATTCCTGGAGGGAGAGATTITGG 240
sbjct 400 CTCTAAATTTTAATATGTCTGTTAGTAGTATGGAATATATTCCTGAGGGAGAGATTTTGG 459
Query 241 TTATAACTTATGGAGGATCTATTGCTTTTCATAGTGCAGTAAGTTTGGACCCAATTAAAT 300
sbjct 460 TTATAACTTATGGACGATCTATTGCTTTTCATAGTGCAGTAAGTTTGGACCCAATTAAAT 519
Query 301 CCTITGAGGCTCCTGCAACCATCAATTCTGCATCTCTTCATCCTGAGAAGGATTTCTTG 360
Query 361 TTGCAGGGGGTGAAGATTTTAAACTTTATAAGTATGATTATAATAGTGGAGAAGAATTAG 420
sbjct 580 HGCAGGCGGTGAAGATtTTAAACTtTATAAGTATGATTATAATAGTGGAGAAGAATTAG 639

Query 481 TCTATGCCAGTGGTTCAGAAGATGGAACATTGAGACTATGGCAAACTGTGGTAGGAAAAA 540
sbjct 700 TCTATGCCAGGGGTYCAGAAGATGGAACATGGAGACTATGGCAAACTGTGGTAGGAAAAA 759
Query 541 CGTATGGCCTTTGGAAATGTGTGCTTCCTGAAGAAGATAGTGGTGAGCTGGCAAAGCCAA 600
sbjct 760 CGTATGGCCT
sbjct 820 |l|1111111111111111111111111111111111111111111 8
Query 661 ATTGCATCTITCCTTCAGCTCCTGATGTTAAGGCCTG 69
sbjct 880 ATTGCATCTTTCCTTCAGCTCCTGATGTTAAGGCCTG 916

Supplemental Figure 6. Alignment of STRAP isoform sequences obtained by Sanger sequencing.


E
erythroid cells


F


G


Supplemental Figure 7. Effects of H2AFY isoform 1.1 knockdown, STRAP knockdown and ITGB3BP overexpression in transduced hematopoietic progenitors differentiated towards the erythroid and granulomonocytic lineages. (A) Apoptosis measured by Annexin V staining and flow cytometry in transduced erythroid cells with $H 2 A F Y$ isoform 1.1 knockdown on day 11 of culture. (B) Cell cycle analysis of transduced erythroid cells with H2AFY isoform 1.1 knockdown on day 11 of culture. (C) Apoptosis measured by Annexin V staining and flow cytometry in transduced granulomonocytic cells with H2AFY isoform 1.1 knockdown on day 11 of culture. (D) Cell cycle analysis of transduced granulomonocytic cells with H2AFY isoform 1.1 knockdown on day 11 of culture. (E) Expression levels of STRAP in erythroid cells transduced with EV, U2AF1WT or U2AF1S34F determined using qRT-PCR. (F) Expression levels of STRAP in granulomonocytic cells transduced with EV, U2AF1WT or U2AF1S34F determined using qRT-PCR. (G) Apoptosis measured by Annexin V staining and flow cytometry in transduced granulomonocytic cells with ITGB3BP overexpression on day 11 of culture. Results in each bar graph in panel (A), (B), (C) and (D) were obtained from 6 independent experiments. Results in each bar graph in panel (E), (F) and (G) were obtained from 5,5 and 6 independent experiments respectively. Bar graphs show mean+SEM. P values were calculated by 1 -way ANOVA with repeated measures using Tukey's post-test. ${ }^{*} \mathrm{P}<0.05,{ }^{* *} \mathrm{P}<0.01$ and ${ }^{* * *} \mathrm{P}<0.001$.

A
erythroid
granulomonocytic
$\begin{array}{cll}\text { MDS } 1 & \text { MDS } 2 \\ \text { EV } & \text { U2AF1WT } & \text { EV } \\ \text { U2AF1WT }\end{array}$



Supplemental Figure 8. Effects of U2AF1 ${ }^{\text {WT }}$ overexpression on U2AF1S34F MDS hematopoietic progenitors differentiated towards the erythroid and granulomonocytic lineages. (A) Expression levels of U2AF1WT in U2AF1S34F MDS erythroid and granulomonocytic cells (day 11) transduced with EV or U2AF1WT determined using Western blotting. (B-D) Effects of U2AF1WT overexpression on erythroid and granulomonocytic differentiation of U2AF1S34F MDS hematopoietic progenitors. (B) Late erythroid (CD71-CD235a ${ }^{+}$) cell population on day 14 of culture, and (C) monocytic (CD14 ${ }^{+}$CD15 ${ }^{-}$) and ( D ) granulocytic (CD14-CD15 ${ }^{+}$) cell populations on day 20 of culture were measured by flow cytometry. (E-F) Ratio of H2AFY isoform 1.1 in EV or U2AF1WT transduced (E) erythroid cells (Day 14) and (F) granulomonocytic cells (Day 20) in culture measured by RT-PCR and gel electrophoresis. (G) Ratio of STRAP short isoform in EV or U2AF1WT transduced erythroid cells (Day 14) in culture was measured by RT-PCR and gel electrophoresis. In panel (E-G), quantification of altered splicing events in gel was performed by ImageJ. Results in each bar graph were obtained from 3 independent experiments in panels ( $\mathrm{E}-\mathrm{G}$ ). Results are shown as mean $\pm$ SEM. P values in panels $\mathrm{E}-\mathrm{G}$ were calculated by 1way ANOVA using Tukey's post-test. ${ }^{*} \mathrm{P}<0.05$, ${ }^{* *} \mathrm{P}<0.01$ and ${ }^{* * *} \mathrm{P}<0.001$.

Supplemental Table 1
Sequence of primers used in this study.

| Name | Sequence (5'>3') | Application |
| :---: | :---: | :---: |
| U2AF1 S34F F | ATGGCGGAGTATCTGGCCTC | Sequencing of U2AF1S34F mutation |
| U2AF1 S34F R | TCAGAATCGCCCAGATCTTT | Sequencing of U2AF1S34F mutation |
| H2AFY shRNA 3 | TCGACAGTGATGCTGTCGT | Knockdown H2AFY isoform 1.1 |
| H2AFY shRNA 4 | GTCGTTCACCCGACAAACA | Knockdown H2AFY isoform 1.1 |
| H2AFY isoform1.1 F | CAGGGTGAAGTCAGTAAGGC | Isoform-specific qRT-PCR and RT-PCR for H2AFY isoform1.1 and total |
| H2AFY isoform1.1 R | CTTCACCACCGATGTAGAAG | Isoform-specific qRT-PCR and RT-PCR for H2AFY isoform1.1 and total |
| H2AFY isoform1.2 F | CTTTGAGGTGGAGGCCATAA | Isoform-specific qRT-PCR for H2AFY isoform1.2 |
| H2AFY isoform1.2 R | CTACTTCCAAGGGCCCGTTC | Isoform-specific qRT-PCR RT-PCR for H2AFY isoform1.2 and total |
| STRAP isoform F | CCTATGCTACGCCAGGGAGATAC | Isoform-specific qRT-PCR for STRAP |
| STRAP isoform R | CTGCGTGAAATCCACAGTCTTGAC | Isoform-specific qRT-PCR for STRAP |
| STRAP ex8 qRT F | CCTACAAGGGCAACTTTGGTCCTA | qRT-PCR for STRAP |
| STRAP ex9 qRT R | CTAGCTCCTCTTCTGTTGTCTCTGG | qRT-PCR for STRAP |
| STRAP ex1 RT F | AATGAGACAGACGCCGCTCA | RT-PCR for STRAP long and short isoform |
| STRAP ex3 RT R | CTGCGTGAAATCCACAGTCTTGAC | RT-PCR for STRAP long and short isoform |
| SMARCA5 F | GAGTACTGCAGGTTGGATGGTCAG | Isoform-specific qRT-PCR for SMARCA5 |
| SMARCA5 R | ACACTCTGACTGTCTTAGTCTGCCC | Isoform-specific qRT-PCR for SMARCA5 |
| ITGB3BP F | CCGTTCACTGCAACATCTGCT | Isoform-specific qRT-PCR for ITGB3BP |
| ITGB3BPR | GCTCTTCAGAACTTGTGGGAGA | Isoform-specific qRT-PCR for ITGB3BP |
| ATR F | TGGAATGGGTCCTATGGGAACAGAGGGT CT | Isoform-specific qRT-PCR for ATR |
| ATR R | GTTCATCAGGATCCTTGTGAGGC | Isoform-specific qRT-PCR for ATR |


| Name | Sequence (5'>3') | Application |
| :--- | :--- | :--- |
| H2AFY Cloning F | GCGGTGGGAAGAAGAAGTCCAC | Cloning of H2AFY to confirm full length <br> isoform expression |
| H2AFY Cloning R | CAGCTTGGCCATTTCCTGCAC | Cloning of H2AFY to confirm full length <br> isoform expression |
| STRAP Cloning F | TGAGACAGACGCCGCTCACCT | Cloning of STRAP to confirm full length <br> isoform expression |
| STRAP Cloning R | CAGGCCTTAACATCAGGAGCTGA | Cloning of STRAP to confirm full length <br> isoform expression |
| hATG7_proximal CP F | GCTGCTGAGATCTGGGACAT | SYBR green qRT-PCR assessment of ATG7 <br> proximal polyadenylation site usage |
| hATG7_proximal CP R | CAGAGGGGGGAATCCCA | SYBR green qRT-PCR assessment of ATG7 <br> proximal polyadenylation site usage |
| hATG7_distal CP F | GGGCATCGTCTTTCCTGCTA | SYBR green qRT-PCR assessment of ATG7 <br> distal polyadenylation site usage |
| hATG7_distal CP R | TGGCTACTTTGGGAGAAGCG | SYBR green qRT-PCR assessment of ATG7 <br> distal polyadenylation site usage |
| U2AF1 pyro F | TTCAAAATTGGAGCATGTCG | U2AF1 S34 Pyrosequencing assay |
| U2AF1 pyro R | Biotin- ATGGTCTGGCTAAACGTCG | U2AF1 S34 Pyrosequencing assay |
| U2AF1 pyro seq | AATTGGAGCATGTCGTC | U2AF1 S34 Pyrosequencing assay |


| Sample ID | Sample name | Lane | Total reads | Total mapped reads | Uniquely mapped number | Intragenic <br> Rate | Intronic <br> Rate | Exonic Rate | Intergenic Rate | Expression Profiling Efficiency | Split <br> Reads | Transcripts Detected | Genes Detected | Mean Per Base Cov. | Mean CV |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| WTCHG_165332_258 | erythroid-empty-1 | one lane | 25546477 | 18616536 | 13535386 | 0.911 | 0.239 | 90.672 | 0.089 | 0.6724 | 6508934 | 24821 | 12737 | 16.79 | 0.935 |
| WTCHG_171117_277 | erythroid-empty-2 | lane1 | 15065510 | 13093191 | 8799374 | 0.912 | 0.203 | 30.708 | 0.088 | 0.7084 | 5790416 | 24073 | 12262 | 13.09 | 0.758 |
| WTCHG_172885_277 | erythroid-empty-2 | lane2 | 13372436 | 11592765 | 7790067 | 0.912 | 0.202 | 20.709 | 0.088 | 0.7093 | 5123537 | 23790 | 12095 | 11.46 | 0.773 |
| WTCHG_171117_278 | erythroid-empty-3 | lane1 | 17861947 | 15460116 | 13198309 | 0.858 | 0.233 | 30.625 | 0.142 | - 0.6246 | 5775406 | 26045 | 13377 | 19.55 | 0.734 |
| WTCHG_172885_278 | erythroid-empty-3 | lane2 | 15959058 | 13798535 | 11784152 | 0.857 | 0.232 | 20.625 | 0.142 | 0.6250 | 5160843 | 25872 | 13268 | 17.29 | 0.749 |
| WTCHG_165332_260 | erythroid-s34f-1 | one lane | 27811937 | 22175539 | 19260331 | 0.871 | 0.248 | 8.623 | 0.128 | 0.6232 | 8450704 | 26094 | 13407 | 30.32 | 0.730 |
| WTCHG_171117_257 | erythroid-s34f-2 | lane1 | 18712942 | 16333021 | 12527116 | 0.878 | 0.176 | 0.702 | 0.122 | 0.7021 | 7175933 | 25724 | 13195 | 20.45 | 0.716 |
| WTCHG_172885_257 | erythroid-s34f-2 | lane2 | 15811020 | 13783768 | 10566838 | 0.877 | 0.175 | 0.702 | 0.123 | 0.7021 | 6061265 | 25416 | 12997 | 17.40 | 0.720 |
| WTCHG_171117_258 | erythroid-s34f-3 | lane1 | 14814430 | 12767234 | 8009230 | 0.934 | 0.175 | - 0.759 | 0.066 | 0.7591 | 5751814 | 23418 | 11876 | 11.48 | 0.777 |
| WTCHG_172885_258 | erythroid-s34f-3 | lane2 | 15067887 | 12979509 | 8148055 | 0.934 | 0.174 | - 0.760 | 0.066 | 0.7598 | 5848850 | 23489 | 11884 | 11.72 | 0.766 |
| WTCHG_165332_259 | erythroid-wt-1 | one lane | 27279491 | 21159579 | 16365090 | 0.882 | 0.253 | 30.628 | 0.118 | - 0.6284 | 6938049 | 25666 | 13237 | 22.58 | 0.919 |
| WTCHG_171117_279 | erythroid-wt-2 | lane1 | 15471495 | 13766562 | 8681376 | 0.936 | 0.177 | 0.759 | 0.064 | 0.7591 | 6501764 | 23754 | 12111 | 13.99 | 0.767 |
| WTCHG_172885_279 | erythroid-wt-2 | lane2 | 14636258 | 13017120 | 8181956 | 0.936 | 0.176 | . 0.760 | 0.063 | 0.7602 | 6158388 | 23548 | 12020 | 13.17 | 0.776 |
| WTCHG_171117_280 | erythroid-wt-3 | lane1 | 16170639 | 14000232 | 8840547 | 0.916 | 0.181 | 0.735 | 0.084 | - 0.7352 | 6361189 | 24313 | 12363 | 13.91 | 0.744 |
| WTCHG_172885_280 | erythroid-wt-3 | lane2 | 15049777 | 13012166 | 8180752 | 0.916 | 0.180 | 0.737 | 0.083 | 0.7366 | 5918893 | 24209 | 12314 | 12.87 | 0.755 |
| WTCHG_165332_261 | granulomonocytic-empty-1 | one lane | 27820205 | 23194583 | 22442598 | 0.884 | 0.188 | 0.697 | 0.115 | - 0.6967 | 9759322 | 26139 | 13462 | 34.91 | 0.802 |
| WTCHG_171117_259 | granulomonocytic-empty-2 | lane1 | 15241845 | 13616677 | 13057942 | 0.872 | 0.246 | - 0.626 | 0.127 | 0.6261 | 5320919 | 25048 | 12834 | 20.05 | 0.730 |
| WTCHG_172885_259 | granulomonocytic-empty-2 | lane2 | 16364139 | 14611988 | 14019233 | 0.873 | 0.246 | - 0.627 | 0.127 | 0.6266 | 5710968 | 25186 | 12916 | 21.59 | 0.742 |
| WTCHG_171117_260 | granulomonocytic-empty-3 | lane1 | 18517334 | 16535205 | 15936610 | 0.890 | 0.202 | 20.688 | 0.110 | 0.6884 | 7178954 | 25633 | 13123 | 25.15 | 0.771 |
| WTCHG_172885_260 | granulomonocytic-empty-3 | lane2 | 16500313 | 14733089 | 14211779 | 0.890 | 0.201 | - 0.689 | 0.110 | 0.6890 | 6409513 | 25467 | 13048 | 22.48 | 0.773 |
| WTCHG_165332_263 | granulomonocytic-s34f-1 | one lane | 29075241 | 24749666 | 23945787 | 0.889 | 0.218 | $8 \quad 0.671$ | 0.111 | 0.6709 | 10011758 | 26437 | 13617 | 35.78 | 0.770 |
| WTCHG_171117_263 | granulomonocytic-s34f-2 | lane1 | 13525385 | 11544333 | 11020753 | 0.846 | 0.236 | - 0.610 | 0.153 | 0.6103 | 4190498 | 23813 | 12198 | 17.59 | 0.831 |
| WTCHG_172885_263 | granulomonocytic-s34f-2 | lane2 | 14143648 | 12069933 | 11533003 | 0.846 | 0.236 | 0.611 | 0.153 | - 0.6106 | 4381522 | 23834 | 12197 | 18.45 | 0.815 |
| WTCHG_171117_264 | granulomonocytic-s34f-3 | lane1 | 15738365 | 13336318 | 12758067 | 0.838 | 0.271 | 0.567 | 0.162 | - 0.5671 | 4414612 | 24711 | 12693 | 18.55 | 0.803 |
| WTCHG_172885_264 | granulomonocytic-s34f-3 | lane2 | 14343654 | 12141383 | 11627026 | 0.837 | 0.270 | 0.567 | 0.163 | - 0.5673 | 4027735 | 24607 | 12639 | 16.76 | 0.784 |
| WTCHG_165332_262 | granulomonocytic-wt-1 | one lane | 28075831 | 22967423 | 22256097 | 0.872 | 0.164 | 0.707 | 0.128 | 0.7073 | 9983910 | 24096 | 12362 | 33.07 | 0.782 |
| WTCHG_171117_261 | granulomonocytic-wt-2 | lane1 | 13504521 | 11713391 | 11157958 | 0.850 | 0.294 | 0.556 | 0.149 | 0.5563 | 3982596 | 24054 | 12323 | 15.93 | 0.791 |
| WTCHG_172885_261 | granulomonocytic-wt-2 | lane2 | 14511454 | 12577442 | 11990629 | 0.851 | 0.294 | 0.556 | 0.149 | - 0.5563 | 4277559 | 24190 | 12369 | 17.09 | 0.813 |
| WTCHG_171117_262 | granulomonocytic-wt-3 | lane1 | 15999726 | 14136893 | 13490820 | 0.880 | 0.184 | 0.696 | 0.120 | 0.6963 | 6127524 | 25572 | 13071 | 20.82 | 0.797 |
| WTCHG_172885_262 | granulomonocytic-wt-3 | lane2 | 17118242 | 15115345 | 14438060 | 0.880 | - 0.184 | - 0.697 | 0.119 | - 0.6968 | . 6556334 | 25623 | 13132 | . 22.24 | 0.780 |

